Sweet’s syndrome associated with FLT3 inhibition - PMC
Here, we report a case of Sweet’s syndrome (SS) associated with gilteritinib that improved with cessation and reoccurred with rechallenge of this and quizartinib, providing a clearer link between this neutrophilic dermatosis and FLT3 inhibition.
【AmBeed聚焦】FLT3的作用机制及相关抑制剂 - 知乎
FLT3的全称是FMS样酪氨酸激酶3（FMS-like tyrosine kinase 3），也称为Flk2 / CD135，是III型受体酪氨酸激酶（RTK），在造血细胞存活、增殖和分化中起重要作用。 FLT3由位于细胞外区域的免疫球蛋白样细胞外结构域、跨膜结构域、近膜结构域（JMD）、酪氨酸激酶结构域中断（TKD）和小的C末端域等5个结构域组成。 在临床上，FLT3基因的激活突变是急性髓细胞性白血病（AML）患者中最常见的遗传变异（约30%左右） [1,2]。
Non-canonical FLT3 alterations reveal novel germline FLT3 …
2024年7月30日 · Being a proto-oncogene, gain-of-function mutations in FLT3 (FLT3 MT) gene create a robust selection pressure on affected myeloid leukemic precursors by alleviating the need for ligand binding .
血液肿瘤中FLT3基因突变分类、相关靶向药和耐药机制 - 好大夫在线
FLT3-ITD 是 FLT3 基因exon14/15的 JMD 全部或 TKD1 部分结构域（aa 572~630）碱基序列的串联重复，多表现为突变序列串联重复3n（n=1~100）个bp的碱基序列，约69.5%的 FLT3-ITD 发生在 JMD 、25.8%的 FLT3-ITD 发生在 TKD1 结构域 β1 sheet （aa 610~615）。
FLT3 is associated with dendritic cell infiltration, tertiary lymphoid ...
2025年1月20日 · FMS-like tyrosine kinase 3 (FLT3) is a frequently mutated gene in acute myeloid leukemia (AML). However, its role in solid cancers remains poorly understood. We analyzed the...
AML治疗常用4种FLT3抑制剂：索拉非尼、米哚妥林、奎扎替尼、 …
FLT3是一种跨膜酪氨酸激酶受体，参与细胞增殖、分化和存活的调控。 在AML患者中，FLT3基因突变非常常见，特别是在FLT3内部串联重复（ITD）和酪氨酸激酶域（TKD）突变。 这些突变的AML患者往往预后更差，且对传统化疗的反应不佳。 FLT3抑制剂的工作机制. 靶向FLT3受体：FLT3（FMS样酪氨酸激酶3）是一种受体酪氨酸激酶，它在正常造血和白血病细胞的增殖、存活和分化中起着关键作用。 FLT3抑制剂通过特异性地结合FLT3受体，阻断其活性。 FLT3抑制 …
FLT3 Mutation: Detailed Discussion on Prognosis and Pathways
6 天之前 · Explore the impact of FLT3 mutations on prognosis, underlying genetic mechanisms, and key pathways, with insights into detection methods and clinical patterns. FLT3 mutations play a significant role in acute myeloid leukemia (AML), influencing disease progression and …
FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR …
FLT3, a type III receptor tyrosine kinase, expresses on most acute leukemia cells as well as normal hematopoietic stem/progenitor cells. Mutation in the FLT3 gene is the most frequent genetic alteration in acute myeloid leukemia (AML) and is well known as an important driver mutation for the development of myeloid malignancies.
Effect of FLT3 ligand on the gene expression of TIM-3, HIF1
4 天之前 · Background Acute Myeloid Leukemia (AML) pathogenesis is driven by the dysregulation of various cell signaling pathways, including the FMS-Like Tyrosine Kinase 3 (FLT3) pathway and its ligand (FLT3L). These pathways play a critical role in promoting cell survival, proliferation, and resistance to apoptosis, contributing to leukemogenesis. In this study, we investigated the effects of FLT3L on ...
Gilteritinib versus salvage chemotherapy in predominantly Asian ...
2025年3月10日 · The COMMODORE study demonstrated the efficacy and safety of gilteritinib versus salvage chemotherapy (SC) treatment in a predominantly Asian population with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-mutated(mut+) acute myeloid leukemia (AML); here we present an exploratory analysis of the study stratified by region (China, South-East Asia and Russia). COMMODORE was a Phase 3 ...